SENS-01
| Clinical data | |
|---|---|
| Synonyms | SENS01 |
| Routes of administration | Unspecified[1] |
| Drug class | Anxiolytic; Psychedelic-related |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
SENS-01 is an experimental drug which is under development for the treatment of social anxiety disorder, other anxiety disorders, and depressive disorders.[1][2][3][4][5][6] Its route of administration is unspecified.[1]
The drug is described by its developer as a novel, selective, and fast-acting anxiolytic without sedation.[4][7][8] Its exact mechanism of action has not yet been disclosed.[1][2] SENS-01 is said to be a synthetic analogue of a naturally occurring anxiolytic that has been validated in humans.[7] Its developer is described as a psychedelic pharmaceutical company[9] and the drug is listed on Psychedelic Alpha's psychedelic drug development tracker, which appear to indicate that it is a psychedelic-related compound.[10]
SENS-01 is being developed by Sensorium Therapeutics.[1][2][6] As of October 2024, it is in the preclinical research stage of development.[1][10] The compound's chemical structure does not yet appear to have been disclosed.[1]
See also
- List of investigational social anxiety disorder drugs
- List of investigational hallucinogens and entactogens
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "SENS 01". AdisInsight. 28 October 2024. Retrieved 17 February 2025.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SENS-01 with Synapse". Synapse. 23 January 2025. Retrieved 17 February 2025.
- ↑ Daigle G, Brown JM (6 October 2024). PSTR056.22 / B30 - Sensorium's Natural Compound product engine generates novel drug discovery program for Epilepsy and Anxiety. Neuroscience 2024. Society for Neuroscience.
- ↑ 4.0 4.1 Laws L (9 November 2022). "Sensorium closes $30M deal to advance drug discovery engine". Labiotech.eu. Retrieved 17 February 2025.
Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform (BDP). [...] The company’s initial asset SENS-01, shows promise to deliver swift therapeutic effect for treating anxiety. Sensorium is developing SENS-01 as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression and expects to begin IND-enabling studies in 2023 and enter the clinic by early 2024.
- ↑ McKenzie H (7 November 2022). "Sensorium Scores $30M to Change Risk-Value Proposition in CNS Drug Discovery". BioSpace. Retrieved 17 February 2025.
Sensorium expects to begin IND-enabling studies for its first asset, SENS-01 for anxiety and depression, in 2023, with plans to enter the clinic by early 2024.
- ↑ 6.0 6.1 Sheridan C (8 November 2022). "Sensorium raises $30M in series A round to probe plants, fungi for psychoactive natural products". BioWorld. Retrieved 17 February 2025.
- ↑ 7.0 7.1 Synapse by patsnap (1 November 2024). "Sensorium Therapeutics Presents Promising Anxiety & Epilepsy Data at Neuroscience 2024". Synapse. Retrieved 17 February 2025.
The SENS-01 program features a novel molecule, a synthetic derivative of a natural compound validated in humans as a fast-acting anxiolytic. This molecule has shown excellent CNS drug-like properties, a clean safety profile, and in vivo efficacy in multiple models. The program is nearing the completion of IND-enabling studies with plans for clinical entry in early 2025. [...] During the Neuroscience 2024 conference, Sensorium presented several poster sessions. One focused on the development of SENS-01, revealing that the anxiolytic candidate is a small molecule synthetic derivative of a natural compound, validated as a fast-onset anxiolytic. Both in vitro and in vivo data confirmed its rapid onset effects, and IND-enabling safety studies indicated a clean safety profile.
- ↑ PR Newswire (10 October 2024). "Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024". PR Newswire. Retrieved 17 February 2025.
- ↑ Psychedelic Alpha (24 January 2023). "Panel: Three Psychedelics Companies that Raised in 2022". Psychedelic Alpha. Retrieved 17 February 2025.
- ↑ 10.0 10.1 Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
External links
- Pipeline - Science - Sensorium Therapeutics
- The Psychedelics Drug Development Tracker - Psychedelic Alpha
 | This psychoactive drug-related article is a stub. You can help EverybodyWiki by expanding it. |
This article "SENS-01" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:SENS-01. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
